

Paul T Monagle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4296958/publications.pdf>

Version: 2024-02-01

346
papers

14,258
citations

32410

55
h-index

29333

108
g-index

350
all docs

350
docs citations

350
times ranked

8699
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet Phenotype and Function Changes With Increasing Duration of Extracorporeal Membrane Oxygenation. <i>Critical Care Medicine</i> , 2022, 50, 1236-1245.	0.4	10
2	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 129.	3.8	37
3	Baby steps in managing CVAD-related thrombosis. <i>Blood</i> , 2022, 139, 321-322.	0.6	0
4	Anticoagulant Treatment for Pediatric Infection-Related Cerebral Venous Thrombosis. <i>Pediatric Neurology</i> , 2022, 128, 20-24.	1.0	4
5	Age-related differences in SARS-CoV-2 binding factors: An explanation for reduced susceptibility to severe COVID-19 among children?. <i>Paediatric Respiratory Reviews</i> , 2022, 44, 61-69.	1.2	6
6	Coagulation in pediatric extracorporeal membrane oxygenation: A systematic review of studies shows lack of standardized reporting. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12687.	1.0	3
7	Increased Risk for Thromboembolism After Fontan Surgery: Considerations for Thromboprophylaxis. <i>Frontiers in Pediatrics</i> , 2022, 10, 803408.	0.9	4
8	Fibrin clot characteristics and anticoagulant response in a SARS-CoV-2-infected endothelial model. <i>EJHaem</i> , 2022, 3, 326-334.	0.4	2
9	Diagnosis and management of severe congenital protein C deficiency (SCPCD): Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1735-1743.	1.9	8
10	The evaluation of overall hemostatic potential assay in patients with COVID-19 infection. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	0.7	2
11	Age partitioned and continuous upper reference limits for Ortho VITROS High Sensitivity Troponin I in a healthy paediatric cohort. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, .	1.4	0
12	Whole blood flow cytometry protocol for the assessment of platelet phenotype, function, and cellular interactions. <i>Platelets</i> , 2021, 32, 786-793.	1.1	8
13	Identification of barriers and enablers to rapid diagnosis along the paediatric stroke chain of recovery using Value-Focused Process Engineering. <i>Health Systems</i> , 2021, 10, 73-88.	0.9	1
14	Bleeding in the Neonate. , 2021, , 395-400.		0
15	Bleeding Disorders. , 2021, , 293-311.		0
16	International pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1123-1129.	1.9	23
17	Paediatric Code Stroke. <i>Journal of Paediatrics and Child Health</i> , 2021, , .	0.4	0
18	Investigating potential protein markers of cardiovascular disease in children with type 1 diabetes mellitus. <i>Proteomics - Clinical Applications</i> , 2021, 15, 2000060.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Social Cognitive Dysfunction Following Pediatric Arterial Ischemic Stroke. <i>Stroke</i> , 2021, 52, 1609-1617.	1.0	4
20	Cross-sectional assessment of haemostatic profile and hepatic dysfunction in Fontan patients. <i>Open Heart</i> , 2021, 8, e001460.	0.9	4
21	Influence of serum iron test results on the diagnosis of iron deficiency in children: a retrospective observational study. <i>BMJ Open</i> , 2021, 11, e046865.	0.8	5
22	Recombinant Factor VIIa in Pediatric Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, , .	0.6	1
23	GRADE notes: How to use GRADE when there is "no" evidence? A case study of the expert evidence approach. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 231-235.	2.4	21
24	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. <i>Blood Advances</i> , 2021, 5, 4721-4726.	2.5	10
25	Long-term outcomes of warfarin versus aspirin after Fontan surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 1218-1228.e3.	0.4	16
26	Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. <i>Journal of Clinical Epidemiology</i> , 2021, 138, 115-127.	2.4	4
27	Fatigue Following Pediatric Arterial Ischemic Stroke. <i>Stroke</i> , 2021, 52, 3286-3295.	1.0	3
28	Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children. <i>Journal of Pediatrics</i> , 2021, , .	0.9	3
29	Vaccine-induced immune thrombosis and thrombocytopenia syndrome following adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a novel hypothesis regarding mechanisms and implications for future vaccine development. <i>Immunology and Cell Biology</i> , 2021, 99, 1006-1010.	1.0	8
30	Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. <i>Vaccine</i> , 2021, 39, 7052-7057.	1.7	24
31	Validating Direct Oral Anticoagulants (DOAC) for Use in Children By the Throm-PED Doac Registry of the International Pediatric Thrombosis Network. <i>Blood</i> , 2021, 138, 1063-1063.	0.6	4
32	Severe COVID-19 and coagulopathy: A systematic review and meta-analysis. <i>Annals of the Academy of Medicine, Singapore</i> , 2021, 50, 325-335.	0.2	4
33	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e18-e27.	2.2	173
34	Management of People With a Fontan Circulation: a Cardiac Society of Australia and New Zealand Position statement. <i>Heart Lung and Circulation</i> , 2020, 29, 5-39.	0.2	42
35	Guidelines for panel design, optimization, and performance of whole blood multi-color flow cytometry of platelet surface markers. <i>Platelets</i> , 2020, 31, 845-852.	1.1	17
36	Anticoagulant Heparin Mimetics via RAFT Polymerization. <i>Biomacromolecules</i> , 2020, 21, 1009-1021.	2.6	16

#	ARTICLE	IF	CITATIONS
37	Cognitive resilience following paediatric stroke: Biological and environmental predictors. <i>European Journal of Paediatric Neurology</i> , 2020, 25, 52-58.	0.7	11
38	Development and Validation of the Warfarin-Aspirin Bleeding Assessment Tool (WA-BAT) in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e513-e514.	0.3	1
39	Risk of traumatic intracranial haemorrhage in children with bleeding disorders. <i>Journal of Paediatrics and Child Health</i> , 2020, 56, 1891-1897.	0.4	4
40	Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). <i>Blood Advances</i> , 2020, 4, 4632-4639.	2.5	35
41	Validation of the HAPPI Kids Continuous Age-Specific Pediatric Reference Intervals. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 1337-1344.	0.6	4
42	Clinical thresholds for diagnosing iron deficiency: comparison of functional assessment of serum ferritin to population based centiles. <i>Scientific Reports</i> , 2020, 10, 18233.	1.6	16
43	Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19 related illness. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3099-3105.	1.9	143
44	Statistical methods used in the estimation of age-specific paediatric reference intervals for laboratory blood tests: A systematic review. <i>Clinical Biochemistry</i> , 2020, 85, 12-19.	0.8	8
45	Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. <i>Blood Advances</i> , 2020, 4, 2351-2365.	2.5	26
46	Challenges and Opportunities in the Pharmacological Treatment of Acute Venous Thromboembolism in Children. <i>Paediatric Drugs</i> , 2020, 22, 385-397.	1.3	2
47	Hot topics in coagulation testing: Important considerations for testing children for bleeding/thrombotic disorders. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 68-74.	0.7	4
48	Platelet Transfusion During Extracorporeal Membrane Oxygenation: Possible Harm, Ongoing Uncertainty*. <i>Pediatric Critical Care Medicine</i> , 2020, 21, 208-209.	0.2	3
49	Do asymptomatic clots in children matter?. <i>Thrombosis Research</i> , 2020, 189, 24-34.	0.8	10
50	After an end-of-life decision: Parents' reflections on living with an end-of-life decision for their child. <i>Journal of Paediatrics and Child Health</i> , 2020, 56, 1060-1065.	0.4	6
51	Age-specific differences in the in vitro anticoagulant effect of Bivalirudin in healthy neonates and children compared to adults. <i>Thrombosis Research</i> , 2020, 192, 167-173.	0.8	4
52	Sulfonated RAFT Copolymers as Heparin Mimetics: Synthesis, Reactivity Ratios, and Anticoagulant Activity. <i>Macromolecular Bioscience</i> , 2020, 20, e2000110.	2.1	9
53	Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think Tank. <i>American Heart Journal</i> , 2020, 224, 138-147.	1.2	0
54	Thrombin dynamics in children with liver disease or extrahepatic portal vein obstruction or shunt. <i>Thrombosis Research</i> , 2020, 188, 65-73.	0.8	6

#	ARTICLE	IF	CITATIONS
55	Are controlled trials of anticoagulation in children feasible?. <i>Lancet Haematology</i> , 2020, 7, e193-e194.	2.2	3
56	Anticoagulation in preterm and term neonates: Why are they special?. <i>Thrombosis Research</i> , 2020, 187, 113-121.	0.8	4
57	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1672-1685.	1.9	52
58	Hematologic concerns in extracorporeal membrane oxygenation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 455-468.	1.0	37
59	Reference intervals for serum cystatin C in neonates and children 30 days to 18 years old. <i>Pediatric Nephrology</i> , 2020, 35, 1959-1966.	0.9	6
60	Plasma Proteomic Analysis Reveals Age-Specific Changes in Platelet- and Endothelial Cell-Derived Proteins and Regulators of Plasma Coagulation and Fibrinolysis. <i>Journal of Pediatrics</i> , 2020, 221, S29-S36.	0.9	6
61	Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). <i>Blood Advances</i> , 2020, 4, 6250-6258.	2.5	49
62	Paediatric Reference Intervals: Current Status, Gaps, Challenges and Future Considerations. , 2020, 41, 43-52.		9
63	Motor function daily living skills 5 years after paediatric arterial ischaemic stroke: a prospective longitudinal study. <i>Developmental Medicine and Child Neurology</i> , 2019, 61, 161-167.	1.1	7
64	Slow progress. How do we shift the paradigm of thinking in pediatric thrombosis and anticoagulation?. <i>Thrombosis Research</i> , 2019, 173, 186-190.	0.8	13
65	Anticoagulation during ECMO in neonatal and paediatric patients. <i>Thrombosis Research</i> , 2019, 173, 172-177.	0.8	52
66	Investigation of the in vitro effect of aspirin and tirofiban in children compared to adults. <i>Thrombosis Research</i> , 2019, 181, 67-70.	0.8	1
67	A multi-national trial of a direct oral anticoagulant in children with cardiac disease: Design and rationale of the Safety of Apixaban On Pediatric Heart disease On the prevention of Embolism (SAXOPHONE) study. <i>American Heart Journal</i> , 2019, 217, 52-63.	1.2	55
68	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. <i>Lancet Haematology</i> , 2019, 6, e500-e509.	2.2	51
69	Platelet Phenotype and Function in the Setting of Pediatric Extracorporeal Membrane Oxygenation (ECMO): A Systematic Review. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 137.	1.1	14
70	Reference Values for 30 Common Biochemistry Analytes Across 5 Different Analyzers in Neonates and Children 30 Days to 18 Years of Age. <i>Clinical Chemistry</i> , 2019, 65, 1317-1326.	1.5	39
71	Decreased placental glypican expression is associated with human fetal growth restriction. <i>Placenta</i> , 2019, 76, 6-9.	0.7	7
72	A prospective, cross-sectional study to establish age-specific reference intervals for neonates and children in the setting of clinical biochemistry, immunology and haematology: the HAPPY Kids study protocol. <i>BMJ Open</i> , 2019, 9, e025897.	0.8	28

#	ARTICLE	IF	CITATIONS
73	Antithrombotic management and thrombosis rates in children postâ€“liver transplantation: A case series and literature review. <i>Pediatric Transplantation</i> , 2019, 23, e13420.	0.5	17
74	Mathematical modelling indicates that lower activity of the haemostatic system in neonates is primarily due to lower prothrombin concentration. <i>Scientific Reports</i> , 2019, 9, 3936.	1.6	4
75	Antiplatelet Therapy Monitoring in Neonates and Children. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 073-085.	1.5	4
76	The natural history of asymptomatic central venous catheterâ€“related thrombosis in critically ill children. <i>Blood</i> , 2019, 133, 857-866.	0.6	38
77	Family history of venous thromboembolism in the paediatric population: The need for a standardized definition. <i>Thrombosis Research</i> , 2019, 173, 91-95.	0.8	4
78	Bleeding and thrombotic events occur early in children on durable ventricular assist devices. <i>Thrombosis Research</i> , 2019, 173, 65-70.	0.8	13
79	Australian Clinical Consensus Guideline: The diagnosis and acute management of childhood stroke. <i>International Journal of Stroke</i> , 2019, 14, 94-106.	2.9	64
80	The enactment stage of end-of-life decision-making for children. <i>Palliative and Supportive Care</i> , 2019, 17, 165-171.	0.6	2
81	Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. an Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation. <i>Blood</i> , 2019, 134, 164-164.	0.6	4
82	Social functioning following pediatric stroke: contribution of neurobehavioral impairment. <i>Developmental Neuropsychology</i> , 2018, 43, 312-328.	1.0	23
83	Pathophysiology of thrombosis and anticoagulation post Fontan surgery. <i>Thrombosis Research</i> , 2018, 172, 204-213.	0.8	31
84	Differentiating arterial ischaemic stroke from migraine in the paediatric emergency department. <i>Developmental Medicine and Child Neurology</i> , 2018, 60, 1117-1122.	1.1	21
85	Heparin mimetics with anticoagulant activity. <i>Medicinal Research Reviews</i> , 2018, 38, 1582-1613.	5.0	45
86	The Pediatric Stroke Outcome Measure. <i>Neurology</i> , 2018, 90, e365-e372.	1.5	15
87	A review of commercially available thrombin generation assays. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 42-48.	1.0	71
88	Antithrombotic therapies in children on durable Ventricular Assist Devices: A literature review. <i>Thrombosis Research</i> , 2018, 172, 194-203.	0.8	13
89	American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. <i>Blood Advances</i> , 2018, 2, 3292-3316.	2.5	273
90	The HAPPI Kids (Harmonising Age Pathology Parameters in Kids) study. <i>Impact</i> , 2018, 2018, 20-22.	0.0	0

#	ARTICLE	IF	CITATIONS
91	Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis. <i>Thrombosis Journal</i> , 2018, 16, 29.	0.9	14
92	Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. <i>Thrombosis Journal</i> , 2018, 16, 34.	0.9	28
93	Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study. <i>Thrombosis Journal</i> , 2018, 16, 31.	0.9	29
94	Identifying low-grade cellular rejection after heart transplantation in children by using gene expression profiling. <i>Physiological Genomics</i> , 2018, 50, 190-196.	1.0	5
95	Management of thrombosis in children and neonates: practical use of anticoagulants in children. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 399-404.	0.9	73
96	Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 854-863.	4.6	43
97	Disseminated intravascular coagulation in paediatrics. <i>Archives of Disease in Childhood</i> , 2017, 102, 187-193.	1.0	39
98	Psychosocial function in the first year after childhood stroke. <i>Developmental Medicine and Child Neurology</i> , 2017, 59, 1027-1033.	1.1	16
99	Prehospital Emergency Care in Childhood Arterial Ischemic Stroke. <i>Stroke</i> , 2017, 48, 1095-1097.	1.0	6
100	Expression of Biglycan in First Trimester Chorionic Villous Sampling Placental Samples and Altered Function in Telomerase-Immortalized Microvascular Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1168-1179.	1.1	10
101	Anticoagulation therapy in neonates, children and adolescents. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 41-47.	0.6	21
102	At last: evidence rather than emotion. <i>Blood</i> , 2017, 129, 2714-2715.	0.6	1
103	Characterization of the coagulation profile in children with liver disease and extrahepatic portal vein obstruction or shunt. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 107-119.	0.3	8
104	Asymptomatic central venous catheter related thrombosis in children: two year follow up. <i>Australian Critical Care</i> , 2017, 30, 110.	0.6	1
105	Accuracy and Reliability of Stroke Diagnosis in the Pediatric Emergency Department. <i>Stroke</i> , 2017, 48, 1198-1202.	1.0	14
106	Quantitative Age-specific Variability of Plasma Proteins in Healthy Neonates, Children and Adults. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 924-935.	2.5	42
107	Improving diagnosis of childhood arterial ischaemic stroke. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 1157-1165.	1.4	9
108	Trajectories of Motor Recovery in the First Year After Pediatric Arterial Ischemic Stroke. <i>Pediatrics</i> , 2017, 140, .	1.0	28

#	ARTICLE	IF	CITATIONS
109	Comment on: Generation and optimization of the self-administered pediatric bleeding questionnaire and its validation as a screening tool for von Willebrand disease. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26725.	0.8	1
110	Early predictors of psychosocial functioning 5 years after paediatric stroke. <i>Developmental Medicine and Child Neurology</i> , 2017, 59, 1034-1041.	1.1	18
111	Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins. <i>Blood Advances</i> , 2017, 1, 1243-1253.	2.5	1
112	Developmental Hemostasis. , 2017, , 1151-1158.e2.		0
113	Low paediatric thrombin generation is caused by an attenuation of prothrombin conversion. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1090-1100.	1.8	21
114	Safety and Efficacy Outcomes of Home and Hospital Warfarin Management Within a Pediatric Anticoagulation Clinic. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 216-220.	0.3	15
115	Importance of post-translational modifications on the function of key haemostatic proteins. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 1-4.	0.5	19
116	Brain attacks and stroke in children. <i>Journal of Paediatrics and Child Health</i> , 2016, 52, 158-163.	0.4	24
117	A conceptual and practical approach to haemostasis in paediatric liver disease. <i>Archives of Disease in Childhood</i> , 2016, 101, 854-859.	1.0	8
118	Neuropsychological Profiles of Children Following Vitamin B12 Deficiency During Infancy: A Case Series. <i>Brain Impairment</i> , 2016, 17, 242-253.	0.5	1
119	Performance of bedside stroke recognition tools in discriminating childhood stroke from mimics. <i>Neurology</i> , 2016, 86, 2154-2161.	1.5	38
120	Neonatal Thrombocytopenia. , 2016, , 305-310.		0
121	Differentiating Childhood Stroke From Mimics in the Emergency Department. <i>Stroke</i> , 2016, 47, 2476-2481.	1.0	42
122	Parental Care-Seeking Behavior and Prehospital Timelines of Care in Childhood Arterial Ischemic Stroke. <i>Stroke</i> , 2016, 47, 2638-2640.	1.0	8
123	Novel perspectives on diagnosis and clinical significance of the post-thrombotic syndrome in children. <i>Expert Review of Hematology</i> , 2016, 9, 965-975.	1.0	9
124	Antithrombin Administration in Extracorporeal Membrane Oxygenation Patients: Putting the Cart Before the Horse*. <i>Pediatric Critical Care Medicine</i> , 2016, 17, 1188-1189.	0.2	9
125	Oral anticoagulant therapy interruption in children: A single centre experience. <i>Thrombosis Research</i> , 2016, 140, 89-93.	0.8	7
126	Oral anticoagulant therapy interruption in children: A single centre experience. <i>Pathology</i> , 2016, 48, S97.	0.3	0

#	ARTICLE	IF	CITATIONS
127	Development of a population pharmacokineticâ€“pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 178-184.	1.1	17
128	Thromboembolism and anticoagulation management in the preterm infant. <i>Seminars in Fetal and Neonatal Medicine</i> , 2016, 21, 50-56.	1.1	8
129	Risk factors and clinical features of acute pulmonary embolism in children from the community. <i>Thrombosis Research</i> , 2016, 138, 86-90.	0.8	27
130	Bleeding in the Neonate. , 2016, , 311-317.		0
131	Removal notice to â€œCharacterisation of the Age-Specific Differences in Platelet Physiology and Functionâ€“[Thromb. Res. 133 (2014) S91]. <i>Thrombosis Research</i> , 2015, 136, 1045.	0.8	0
132	Thrombophilia testing in a tertiary paediatric hospital: Indications, outcomes and appropriateness. <i>Journal of Paediatrics and Child Health</i> , 2015, 51, 1017-1022.	0.4	1
133	Remote Ischemic Preconditioning (RIPC) Modifies the Plasma Proteome in Children Undergoing Repair of Tetralogy of Fallot: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0122778.	1.1	15
134	Monitoring Central Venous Catheter Resistance to Predict Imminent Occlusion: A Prospective Pilot Study. <i>PLoS ONE</i> , 2015, 10, e0135904.	1.1	9
135	Cardiopulmonary bypass changes the plasma proteome in children undergoing tetralogy of Fallot repair. <i>Perfusion (United Kingdom)</i> , 2015, 30, 556-564.	0.5	7
136	Differences in the mechanism of blood clot formation and nanostructure in infants and children compared with adults. <i>Thrombosis Research</i> , 2015, 136, 1303-1309.	0.8	35
137	Topical use of antithrombotics: Review of literature. <i>Thrombosis Research</i> , 2015, 135, 575-581.	0.8	10
138	Differences in the resting platelet proteome and platelet releasate between healthy children and adults. <i>Journal of Proteomics</i> , 2015, 123, 78-88.	1.2	22
139	Congenital abnormalities of the inferior vena cava presenting clinically in adolescent males. <i>Thrombosis Research</i> , 2015, 135, 648-651.	0.8	12
140	Recommendations for the development of new anticoagulant drugs for pediatric use: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 481-484.	1.9	12
141	Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis: discussion. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 690-691.	1.9	4
142	Parents and end-of-life decision-making for their child: roles and responsibilities. <i>BMJ Supportive and Palliative Care</i> , 2015, 5, 240-248.	0.8	21
143	Factors Associated with Six-Month Outcome of Pediatric Stroke. <i>International Journal of Stroke</i> , 2015, 10, 1068-1073.	2.9	29
144	Inhalational use of antithrombotics in humans: Review of the literature. <i>Thrombosis Research</i> , 2015, 136, 1059-1066.	0.8	14

#	ARTICLE	IF	CITATIONS
145	Thrombosis Research Editorial. Thrombosis Research, 2015, 136, 697-698.	0.8	1
146	Platelets from children are hyperresponsive to activation by thrombin receptor activator peptide and adenosine diphosphate compared to platelets from adults. British Journal of Haematology, 2015, 168, 526-532.	1.2	26
147	Risk Factors for Neonatal Thrombosis in the Neonatal Intensive Care Unit -a Case Control Study. Blood, 2015, 126, 1109-1109.	0.6	0
148	Epidemiology of venous thrombosis in children with cancer. Thrombosis and Haemostasis, 2014, 111, 1015-1021.	1.8	33
149	The utility of dried blood spots for proteomic studies: Looking forward to looking back. Proteomics - Clinical Applications, 2014, 8, 896-900.	0.8	18
150	What parents want from doctors in end-of-life decision-making for children. Archives of Disease in Childhood, 2014, 99, 216-220.	1.0	52
151	Congenital heart disease and thrombosis: what do we know?. Nature Reviews Cardiology, 2014, 11, 132-134.	6.1	10
152	Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children. Journal of Thrombosis and Haemostasis, 2014, 12, 1554-1557.	1.9	19
153	Stroke and nonstroke brain attacks in children. Neurology, 2014, 82, 1434-1440.	1.5	87
154	Beta (2)-antithrombin activity in children and adults: implications for heparin therapy in infants and children. Journal of Thrombosis and Haemostasis, 2014, 12, 1141-1144.	1.9	11
155	Subcutaneous protein C concentrate in the management of severe protein C deficiency " experience from 12 centres. British Journal of Haematology, 2014, 164, 414-421.	1.2	26
156	Endogenous glycosaminoglycan anticoagulation in extracorporeal membrane oxygenation. Critical Care, 2014, 18, 636.	2.5	5
157	Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding. Blood Coagulation and Fibrinolysis, 2014, 25, 326-332.	0.5	9
158	The in-vitro anticoagulant effect of rivaroxaban in neonates. Blood Coagulation and Fibrinolysis, 2014, 25, 237-240.	0.5	28
159	Dedicated paediatric teaching remains critical to the undergraduate medical curriculum. Journal of Paediatrics and Child Health, 2014, 50, 949-951.	0.4	0
160	Personalised anticoagulation approach to improve the prevention and treatment of thrombosis. Thrombosis Research, 2014, 134, 204-206.	0.8	0
161	Anticoagulation of cardiomyopathy in children. Thrombosis Research, 2014, 134, 255-258.	0.8	4
162	Vintage venoms: Proteomic and pharmacological stability of snake venoms stored for up to eight decades. Journal of Proteomics, 2014, 105, 285-294.	1.2	12

#	ARTICLE	IF	CITATIONS
163	Developmental haemostasis: age-specific differences in the quantity of hemostatic proteins: reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 286-286.	1.9	1
164	Challenges and Priorities for Research. <i>Circulation</i> , 2014, 130, 1192-1203.	1.6	28
165	Reporting haemostatic protein measurements: The time has come to standardise terminology. <i>Thrombosis Research</i> , 2014, 133, 693-694.	0.8	1
166	Altered decorin leads to disrupted endothelial cell function: A possible mechanism in the pathogenesis of fetal growth restriction?. <i>Placenta</i> , 2014, 35, 596-605.	0.7	21
167	Long-term Follow-up of Homozygote Protein C Deficiency After Multimodal Therapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e452-e455.	0.3	15
168	Abstract 37: Pediatric Brain Attacks: Differentiating Between Stroke and Mimics in the Emergency Room.. <i>Stroke</i> , 2014, 45, .	1.0	5
169	Developmental hemostasis: age-specific differences in the levels of hemostatic proteins. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1850-1854.	1.9	156
170	“I don't want to hurt him.” Parents' experiences of learning to administer clotting factor to their child. <i>Haemophilia</i> , 2013, 19, 206-211.	1.0	20
171	Recommendations for point-of-care home International Normalized Ratio testing in children on vitamin K antagonist therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 366-368.	1.9	11
172	Quality of life assessment in children commencing home INR self-testing. <i>Thrombosis Research</i> , 2013, 132, 37-43.	0.8	30
173	Factors Associated With Thrombotic Complications After the Fontan Procedure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 346-353.	1.2	135
174	The economic costs of routine INR monitoring in infants and children – Examining point-of-care devices used within the home setting compared to traditional anticoagulation clinic monitoring. <i>Thrombosis Research</i> , 2013, 132, 26-31.	0.8	12
175	Hospitalisations for sickle-cell disease in an Australian paediatric population. <i>Journal of Paediatrics and Child Health</i> , 2013, 49, 68-71.	0.4	5
176	Latent Antithrombin Levels in Children and Adults. <i>Thrombosis Research</i> , 2013, 131, 105-106.	0.8	15
177	Hypertension at time of diagnosis and long-term outcome after childhood ischemic stroke. <i>Neurology</i> , 2013, 80, 1225-1230.	1.5	25
178	Thrombosis in Paediatrics: Genetic versus Environmental Risk Factors and Implications for Management. <i>Pediatric and Adolescent Medicine</i> , 2013, , 30-41.	0.4	0
179	Inherited Thrombophilias and Adverse Pregnancy Outcomes. <i>Obstetric Anesthesia Digest</i> , 2013, 33, 50.	0.0	0
180	First Report of Elevated Monocyte-Platelet Aggregates in Healthy Children. <i>PLoS ONE</i> , 2013, 8, e67416.	1.1	22

#	ARTICLE	IF	CITATIONS
181	Alpha-2-Macroglobulin Is a Major Determinant Of a Lower Thrombin Generation In Infants and Children Compared To Adults. <i>Blood</i> , 2013, 122, 2344-2344.	0.6	3
182	The First Report Of Differences In Fibrin Clot Nanostructure and Response To Tissue Plasminogen Activator (TPA) and Unfractionated Heparin (UFH) In Infants Compared To Adults. <i>Blood</i> , 2013, 122, 459-459.	0.6	1
183	HEEADSSS assessment for adolescents requiring anticoagulation therapy: Table 1. <i>Archives of Disease in Childhood</i> , 2012, 97, 430-433.	1.0	14
184	Diagnosis and Management of Deep Venous Thrombosis and Pulmonary Embolism in Neonates and Children. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 683-690.	1.5	14
185	Association Between Physical Activity and Risk of Bleeding in Children With Hemophilia. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1452.	3.8	104
186	The Expression of Placental Proteoglycans in Pre-Eclampsia. <i>Gynecologic and Obstetric Investigation</i> , 2012, 73, 277-284.	0.7	37
187	Letter to the Editor regarding the effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 566.	0.5	1
188	Antithrombotic Therapy in Neonates and Children. <i>Chest</i> , 2012, 141, e737S-e801S.	0.4	1,229
189	Heparin concentrations in neonates during cardiopulmonary bypass: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1972-1972.	1.9	1
190	The preterm infant with thrombosis. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2012, 97, F423-F428.	1.4	33
191	A clinical audit of antithrombin concentrate use in a tertiary paediatric centre. <i>Journal of Paediatrics and Child Health</i> , 2012, 48, 681-684.	0.4	12
192	An adolescent patient with post-thrombotic syndrome achieves excellence in sport. <i>Journal of Paediatrics and Child Health</i> , 2012, 48, E190-3.	0.4	2
193	Anticoagulation in children. <i>Thrombosis Research</i> , 2012, 130, 142-146.	0.8	14
194	Placental Syndecan Expression Is Altered in Human Idiopathic Fetal Growth Restriction. <i>American Journal of Pathology</i> , 2012, 180, 693-702.	1.9	25
195	Recommendations for measuring health-related quality of life in children on anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2596-2598.	1.9	6
196	The in vitro anticoagulant effect of rivaroxaban in children. <i>Thrombosis Research</i> , 2012, 130, 804-807.	0.8	37
197	The impact of Cardiopulmonary bypass on Factor XIII levels in children. <i>Thrombosis Research</i> , 2012, 130, e238-e239.	0.8	4
198	Heparin therapy: A potential risk factor for fractures in preterm neonates. <i>Journal of Neonatal-Perinatal Medicine</i> , 2012, 5, 87-90.	0.4	2

#	ARTICLE	IF	CITATIONS
199	Recommendations for developing uniform laboratory monitoring of heparinoid anticoagulants in children. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 145-147.	1.9	7
200	Developmental hemostasis: recommendations for laboratories reporting pediatric samples. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 298-300.	1.9	66
201	Definition of post-thrombotic syndrome following lower extremity deep venous thrombosis and standardization of outcome measurement in pediatric clinical investigations. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 477-480.	1.9	51
202	The PAI-1 4G/5G polymorphism is not associated with an increased risk of adverse pregnancy outcome in asymptomatic nulliparous women. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 881-886.	1.9	17
203	Inherited thrombophilias and adverse pregnancy outcomes: a case-control study in an Australian population. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2012, 91, 250-255.	1.3	36
204	Infant deaths due to heparin overdose: Time for a concerted action on prevention. <i>Journal of Paediatrics and Child Health</i> , 2012, 48, 380-381.	0.4	16
205	Australian Paediatric Surveillance Unit study of haemoglobinopathies in Australian children. <i>Journal of Paediatrics and Child Health</i> , 2012, 48, 356-360.	0.4	4
206	The Quantitative and Qualitative Responses of Platelets in Pediatric Patients Undergoing Cardiopulmonary Bypass Surgery. <i>Pediatric Cardiology</i> , 2012, 33, 55-59.	0.6	14
207	Plasmin Generation and Fibrinolysis in Pediatric Patients Undergoing Cardiopulmonary Bypass Surgery. <i>Pediatric Cardiology</i> , 2012, 33, 280-285.	0.6	8
208	Updates in thrombosis in pediatrics: where are we after 20 years?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 439-443.	0.9	26
209	Updates in thrombosis in pediatrics: where are we after 20 years?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 439-443.	0.9	49
210	Remote Ischemic Preconditioning (RIPC) Modifies Plasma Proteome in Humans. <i>PLoS ONE</i> , 2012, 7, e48284.	1.1	69
211	Developmental haemostasis: Secondary haemostasis. <i>Seminars in Fetal and Neonatal Medicine</i> , 2011, 16, 294-300.	1.1	61
212	Assessing outcome measures of oral anticoagulation management in children. <i>Thrombosis Research</i> , 2011, 127, 75-80.	0.8	25
213	The contribution of Tissue Factor Pathway Inhibitor to Thrombin Generation in children receiving Unfractionated Heparin. <i>Thrombosis Research</i> , 2011, 127, 275-276.	0.8	4
214	We worry about our aim, when we don't even know the target. <i>Thrombosis Research</i> , 2011, 127, 493.	0.8	1
215	Compliance of antithrombotic management at a tertiary paediatric hospital with international guidelines: A 100-Day audit. <i>Thrombosis Research</i> , 2011, 128, 135-140.	0.8	7
216	A Multicenter, Randomized Trial Comparing Heparin/Warfarin and Acetylsalicylic Acid as Primary Thromboprophylaxis for 2 Years After the Fontan Procedure in Children. <i>Journal of the American College of Cardiology</i> , 2011, 58, 645-651.	1.2	216

#	ARTICLE	IF	CITATIONS
217	Thrombosis in Pediatric Intensive Care. , 2011, , 1140-1150.		0
218	Need for a new paediatric post thrombotic sequelae outcome measure for non-extremity thrombosis. Thrombosis and Haemostasis, 2011, 105, 1105-1106.	1.8	1
219	Age-Related Differences in Plasma Proteins: How Plasma Proteins Change from Neonates to Adults. PLoS ONE, 2011, 6, e17213.	1.1	106
220	Evidence for age-related differences in human fibrinogen. Blood Coagulation and Fibrinolysis, 2011, 22, 110-117.	0.5	38
221	Heparin in the long-term management of ligneous conjunctivitis. Blood Coagulation and Fibrinolysis, 2011, 22, 606-609.	0.5	17
222	Who controls the controllers?. Blood, 2011, 117, 1778-1779.	0.6	3
223	Stability and sterility of diluted enoxaparin under three different storage conditions. Journal of Paediatrics and Child Health, 2011, 47, 299-301.	0.4	4
224	Effect of warfarin on menstruation and menstrual management of the adolescent on warfarin. Journal of Paediatrics and Child Health, 2011, 47, 893-897.	0.4	19
225	Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. Journal of Thrombosis and Haemostasis, 2011, 9, 1856-1858.	1.9	148
226	Comparison of "time within therapeutic INR range"™ with "percentage INR within therapeutic range"™ for assessing long-term anticoagulation control in children: a rebuttal. Journal of Thrombosis and Haemostasis, 2011, 9, 2331-2332.	1.9	5
227	Hemostatic Response in Paediatric Patients Undergoing Cardiopulmonary Bypass Surgery. Pediatric Cardiology, 2011, 32, 621-627.	0.6	12
228	Impact of Persistent Antiphospholipid Antibodies on Risk of Incident Symptomatic Thromboembolism in Children: A Systematic Review and Meta-Analysis. Seminars in Thrombosis and Hemostasis, 2011, 37, 802-809.	1.5	50
229	The Coagulation System in Children: Developmental and Pathophysiological Considerations. Seminars in Thrombosis and Hemostasis, 2011, 37, 723-729.	1.5	76
230	Clinical outcomes of management of CVAD occlusions. Archives of Disease in Childhood, 2011, 96, 885-887.	1.0	9
231	Bereaved Parents' Perceptions of the Autopsy Examination of Their Child. Pediatrics, 2011, 127, e1013-e1020.	1.0	31
232	Developmental Hemostasis. , 2011, , 1538-1547.		2
233	Inherited Thrombophilia Polymorphisms and Pregnancy Outcomes in Nulliparous Women. Obstetrics and Gynecology, 2010, 115, 5-13.	1.2	98
234	Novel paediatric anticoagulants: a review of the current literature. Blood Coagulation and Fibrinolysis, 2010, 21, 144-151.	0.5	23

#	ARTICLE	IF	CITATIONS
235	Occlusive aortic arch thrombus in a preterm neonate. <i>Pediatric Critical Care Medicine</i> , 2010, 11, e13-e15.	0.2	9
236	Inherited Thrombophilia Polymorphisms and Pregnancy Outcomes in Nulliparous Women. <i>Obstetrics and Gynecology</i> , 2010, 115, 1305-1306.	1.2	0
237	Decorin expression is decreased in human idiopathic fetal growth restriction. <i>Reproduction, Fertility and Development</i> , 2010, 22, 949.	0.1	27
238	Altered reference ranges for protein C and protein S during early pregnancy: Implications for the diagnosis of protein C and protein S deficiency during pregnancy. <i>Thrombosis and Haemostasis</i> , 2010, 103, 984-988.	1.8	44
239	The in vitro response to low-molecular-weight heparin is not age-dependent in children. <i>Thrombosis and Haemostasis</i> , 2010, 103, 855-856.	1.8	14
240	Placental Biglycan Expression is Decreased in Human Idiopathic Fetal Growth Restriction. <i>Placenta</i> , 2010, 31, 712-717.	0.7	23
241	Hemostasis in neonates and children: Pitfalls and dilemmas. <i>Blood Reviews</i> , 2010, 24, 63-68.	2.8	116
242	Anticoagulation in neonates and children: Pitfalls and dilemmas. <i>Blood Reviews</i> , 2010, 24, 151-162.	2.8	29
243	Age-specific differences in binding of heparin to plasma proteins. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1290-1294.	1.9	45
244	Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children. <i>British Journal of Haematology</i> , 2010, 149, 734-738.	1.2	66
245	research paper: Clinical use of unfractionated heparin therapy in children: time for change?. <i>British Journal of Haematology</i> , 2010, 150, 674-678.	1.2	30
246	Novel interactions between UFH and TFPI in children. <i>British Journal of Haematology</i> , 2010, 151, 376-380.	1.2	8
247	Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1085-1090.	1.8	50
248	Correlation of thromboelastography with standard tests of anticoagulation in paediatric patients receiving extracorporeal life support. <i>Thrombosis Research</i> , 2010, 125, 387-392.	0.8	72
249	Evaluation of a Post-operative Thrombin Inhibitor Replacement Protocol to reduce Haemorrhagic and Thrombotic Complications after Paediatric Liver Transplantation. <i>Thrombosis Research</i> , 2010, 126, 191-194.	0.8	22
250	Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children. <i>Circulation</i> , 2010, 121, 1838-1847.	1.6	383
251	Hyperhaemolysis in sickle cell disease – an unusual and potentially life-threatening complication. <i>Medical Journal of Australia</i> , 2010, 192, 281-282.	0.8	6
252	Unfractionated Heparin Therapy in Infants and Children. <i>Pediatrics</i> , 2009, 123, e510-e518.	1.0	96

#	ARTICLE	IF	CITATIONS
253	In vivo age dependency of unfractionated heparin in infants and children. <i>Thrombosis Research</i> , 2009, 123, 710-714.	0.8	54
254	Point-of-care monitoring of oral anticoagulation therapy in children. <i>Thrombosis and Haemostasis</i> , 2009, 102, 159-165.	1.8	41
255	Anticoagulation in Children. <i>Fundamental and Clinical Cardiology</i> , 2009, , 237-252.	0.0	0
256	Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies.. <i>Blood</i> , 2009, 114, 3993-3993.	0.6	0
257	Arterial thromboembolic disease: A single-centre case series study. <i>Journal of Paediatrics and Child Health</i> , 2008, 44, 28-32.	0.4	36
258	Letter to the Editor regarding "Routine coagulation tests in newborn and infants". <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 161-162.	1.0	0
259	Estimation of transient increases in bleeding risk associated with physical activity in children with haemophilia. <i>BMC Hematology</i> , 2008, 8, 2.	2.6	3
260	Optimising anticoagulant education in the paediatric setting using a validated model of education. <i>Patient Education and Counseling</i> , 2008, 73, 384-388.	1.0	11
261	The prevalence of inherited thrombophilic polymorphisms in an asymptomatic Australian antenatal population. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2008, 48, 536-541.	0.4	14
262	Audit of Nurses- Adherence to Pre-transfusion Checking. <i>Transfusion Medicine</i> , 2008, 15, 69-82.	0.5	0
263	The differences of platelet response to snake venoms: A comparative study of children and adults. <i>Toxicon</i> , 2008, 52, 960-963.	0.8	2
264	Enoxaparin for neonatal thrombosis: A call for a higher dose for neonates. <i>Thrombosis Research</i> , 2008, 122, 826-830.	0.8	102
265	The in vitro anticoagulant effects of Danaparoid, Fondaparinux, and Lepirudin in children compared to adults. <i>Thrombosis Research</i> , 2008, 122, 709-714.	0.8	15
266	Antithrombotic Therapy in Neonates and Children. <i>Chest</i> , 2008, 133, 887S-968S.	0.4	602
267	Impact of Inherited Thrombophilia on Venous Thromboembolism in Children. <i>Circulation</i> , 2008, 118, 1373-1382.	1.6	268
268	Perinatal and early childhood stroke and thrombophilia. <i>Pathology</i> , 2008, 40, 116-123.	0.3	11
269	Thromboembolism in Infants and Children With Gastrointestinal Failure Receiving Long-Term Parenteral Nutrition. <i>Journal of Parenteral and Enteral Nutrition</i> , 2008, 32, 88-93.	1.3	31
270	Assessing the Outcome of Systemic Tissue Plasminogen Activator for the Management of Venous and Arterial Thrombosis in Pediatrics. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 269-273.	0.3	30

#	ARTICLE	IF	CITATIONS
271	Reference Values for Kaolin-Activated Thromboelastography in Healthy Children. <i>Anesthesia and Analgesia</i> , 2007, 105, 1610-1613.	1.1	118
272	Monitoring Unfractionated Heparin (UFH) therapy: Which Anti Factor Xa assay is appropriate?. <i>Thrombosis Research</i> , 2007, 120, 347-351.	0.8	108
273	Thrombin generation: the functional role of alpha-2-macroglobulin and influence of developmental haemostasis. <i>British Journal of Haematology</i> , 2007, 138, 366-368.	1.2	41
274	Temporal Aspects of Anti-Heparin-PF4 Antibodies in Heparin-Induced Thrombocytopenia. <i>Annals of Thoracic Surgery</i> , 2006, 81, 1944.	0.7	2
275	Acute idiopathic portal vein thrombosis in a child: A case report and literature review. <i>Thrombosis Research</i> , 2006, 117, 279-281.	0.8	3
276	Home INR monitoring of oral anticoagulant therapy in children using the CoaguChekâ„¢ S point-of-care monitor and a robust education program. <i>Thrombosis Research</i> , 2006, 118, 587-593.	0.8	49
277	Pediatric edition thrombosis research. <i>Thrombosis Research</i> , 2006, 118, 1-2.	0.8	10
278	Age-related differences in heparin response. <i>Thrombosis Research</i> , 2006, 118, 741-745.	0.8	102
279	Developmental haemostasis. <i>Thrombosis and Haemostasis</i> , 2006, 95, 362-372.	1.8	466
280	Brachial Artery Thrombosis in Infants: An Algorithm for Limb Salvage. <i>Plastic and Reconstructive Surgery</i> , 2006, 117, 1481-1488.	0.7	33
281	Venous thromboembolic disease: A single-centre case series study. <i>Journal of Paediatrics and Child Health</i> , 2006, 42, 803-807.	0.4	47
282	Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2280-2283.	1.9	72
283	A Survey of Pediatric Cardiology Nursesâ€™ Understanding of Warfarin Therapy. <i>Pediatric Cardiology</i> , 2006, 27, 204-208.	0.6	8
284	Oral Anticoagulant Thromboprophylaxis for Kawasaki Disease. <i>Pediatric Cardiology</i> , 2006, 27, 301-301.	0.6	2
285	Bleeding disorders in teenagers presenting with menorrhagia. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2005, 45, 439-443.	0.4	80
286	Thrombosis in children with BT shunts, Glenns and Fontans. <i>Progress in Pediatric Cardiology</i> , 2005, 21, 17-21.	0.2	30
287	Reply to rebuttal: A problem of calibration in the paper â€œPoint of care monitoring of oral anticoagulant therapy in childrenâ€™. <i>Thrombosis and Haemostasis</i> , 2005, 93, 623-623.	1.8	0
288	Hemostatic abnormalities. , 2005, , 310-348.		7

#	ARTICLE	IF	CITATIONS
289	Reduced Bone Density in Children on Long-Term Warfarin. <i>Pediatric Research</i> , 2005, 57, 578-581.	1.1	132
290	Patient understanding of warfarin therapy: A review of education strategies. <i>Hematology</i> , 2005, 10, 437-442.	0.7	36
291	Point of care monitoring of oral anticoagulant therapy in children: comparison of CoaguChek Plus and Thrombotest methods with venous international normalised ratio. <i>Thrombosis and Haemostasis</i> , 2004, 92, 734-737.	1.8	31
292	Reduced Bone Density Among Children With Severe Hemophilia. <i>Pediatrics</i> , 2004, 114, e177-e181.	1.0	121
293	Binding of heparin to plasma proteins and endothelial surfaces is inhibited by covalent linkage to antithrombin. <i>Thrombosis and Haemostasis</i> , 2004, 91, 1009-1018.	1.8	31
294	Impaired Fibrinolytic Activity Is Present in Children with Dyslipidemias. <i>Pediatric Research</i> , 2004, 55, 576-580.	1.1	10
295	Anticoagulation in the young. <i>British Heart Journal</i> , 2004, 90, 808-812.	2.2	27
296	Antithrombotic Therapy in Children*. <i>Chest</i> , 2004, 126, 645S-687S.	0.4	370
297	Arterial ischaemic stroke in children. <i>Journal of Paediatrics and Child Health</i> , 2004, 40, 384-387.	0.4	64
298	Rebuttal to: Clinical manifestations of the prothrombin G20210A mutation in children. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 370-371.	1.9	0
299	Neonatal thrombosis and its treatment. <i>Blood Reviews</i> , 2004, 18, 75-84.	2.8	88
300	Anticoagulation clinics for children achieve improved warfarin management. <i>Thrombosis Research</i> , 2004, 114, 5-9.	0.8	42
301	Developmental Hemostasis. , 2004, , 1435-1447.		4
302	Thrombophilia interpretation in childhood stroke: a cautionary tale. <i>Journal of Child Neurology</i> , 2004, 19, 218-9.	0.7	3
303	Venous thrombosis in children. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1443-1455.	1.9	203
304	Heparin-induced thrombocytopenia in children. <i>Journal of Paediatrics and Child Health</i> , 2003, 39, 289-292.	0.4	87
305	MRA versus angiogram for the diagnosis of peripheral arterial disease, a case report. <i>Thrombosis Research</i> , 2003, 112, 43-45.	0.8	0
306	General anaesthesia or conscious sedation for painful procedures in childhood cancer: the family's perspective. <i>Archives of Disease in Childhood</i> , 2003, 88, 253-257.	1.0	51

#	ARTICLE	IF	CITATIONS
307	Warfarin Therapy in Children Who Require Long-Term Total Parenteral Nutrition. <i>Pediatrics</i> , 2003, 112, e386-e386.	1.0	68
308	Thrombosis in Pediatric Cardiac Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 547-556.	1.5	35
309	Fibrinolytic response to venous occlusion is decreased in patients after Kawasaki disease. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 181-186.	0.5	18
310	Fibrinolytic System in Adolescents: Response to Venous Occlusion Stress Tests. <i>Pediatric Research</i> , 2003, 53, 333-337.	1.1	19
311	Fibrinolytic System in Adolescents: Response to Venous Occlusion Stress Tests. <i>Pediatric Research</i> , 2003, 53, 333-337.	1.1	6
312	Thromboembolic problems after the Fontan operation. <i>Pediatric Cardiac Surgery Annual</i> , 2002, 5, 36-47.	0.5	103
313	Tiger snake envenomation and disseminated intravascular coagulation (DIC). <i>Pathology</i> , 2002, 34, 481.	0.3	3
314	Post-thrombotic syndrome. <i>Archives of Disease in Childhood</i> , 2002, 86, 212-214.	1.0	47
315	Perinatal Management of Patients at High Risk of Homozygous Protein C Deficiency. <i>Thrombosis and Haemostasis</i> , 2002, 88, 370-371.	1.8	22
316	Decreased Concentrations of Heparinoids Are Required to Inhibit Thrombin Generation in Plasma from Newborns and Children Compared to Plasma from Adults due to Reduced Thrombin Potential. <i>Thrombosis and Haemostasis</i> , 2002, 87, 606-613.	1.8	53
317	Thromboembolic complications related to indwelling central venous catheters in children with oncological/haematological diseases: a retrospective study of 362 catheters. <i>Supportive Care in Cancer</i> , 2002, 10, 256-257.	1.0	6
318	Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. <i>British Journal of Haematology</i> , 2002, 116, 178-186.	1.2	158
319	Change in serum procalcitonin (Pct) predicts the clinical outcome of children admitted with febrile neutropenia. <i>British Journal of Haematology</i> , 2002, 118, 1197-1197.	1.2	13
320	Organ retention following paediatric and perinatal autopsy: Where to from here?. <i>Journal of Paediatrics and Child Health</i> , 2002, 38, 405-408.	0.4	2
321	Sedation practices for Australian and New Zealand paediatric oncology patients. <i>Journal of Paediatrics and Child Health</i> , 2002, 38, 170-172.	0.4	14
322	Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. <i>Thrombosis and Haemostasis</i> , 2002, 87, 606-13.	1.8	7
323	Perinatal management of patients at high risk of homozygous protein C deficiency. <i>Thrombosis and Haemostasis</i> , 2002, 88, 370-1.	1.8	3
324	Thromboembolic Disease and Antithrombotic Therapy in Newborns. <i>Hematology American Society of Hematology Education Program</i> , 2001, 2001, 358-374.	0.9	86

#	ARTICLE	IF	CITATIONS
325	Haemostatic Changes following the Modified Fontan Procedure. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1341-1341.	1.8	4
326	Antithrombotic Therapy in Children. <i>Chest</i> , 2001, 119, 344S-370S.	0.4	240
327	Capillary Whole Blood Monitoring of Oral Anticoagulants in Children in Outpatient Clinics and the Home Setting. <i>Pediatric Cardiology</i> , 2000, 21, 347-352.	0.6	82
328	The use of low molecular weight heparin in pediatric patients: A prospective cohort study. <i>Journal of Pediatrics</i> , 2000, 136, 439-445.	0.9	273
329	Outcome of Pediatric Thromboembolic Disease: A Report from the Canadian Childhood Thrombophilia Registry. <i>Pediatric Research</i> , 2000, 47, 763-766.	1.1	459
330	Spontaneous arterial thrombosis in children. <i>Journal of Pediatrics</i> , 1999, 134, 110-112.	0.9	15
331	Editorial: Thromboembolic Complications After Fontan Procedures—The Role Of Prophylactic Anticoagulation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1998, 115, 493-498.	0.4	151
332	Central venous catheter related thrombosis in children: Analysis of the Canadian Registry of Venous Thromboembolic Complications. <i>Journal of Pediatrics</i> , 1998, 133, 770-776.	0.9	403
333	Influence of Mechanical Stretch on Thrombin Regulation by Fetal Mixed Lung Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1998, 19, 419-425.	1.4	7
334	Covalent Heparin Cofactor II-Heparin and Heparin Cofactor II-Dermatan Sulfate Complexes. <i>Journal of Biological Chemistry</i> , 1998, 273, 33566-33571.	1.6	11
335	Prothrombotic Disorders in Infants and Children With Cerebral Thromboembolism. <i>Archives of Neurology</i> , 1998, 55, 1539.	4.9	258
336	Antithrombotic Therapy in Children. <i>Chest</i> , 1998, 114, 748S-769S.	0.4	179
337	Anticoagulation Therapy in Pediatric Patients With Sinovenous Thrombosis. <i>Archives of Neurology</i> , 1998, 55, 1533.	4.9	159
338	Dalteparin for deep enous thrombosis: a hospitalâ€”inâ€”theâ€”home program. <i>Medical Journal of Australia</i> , 1998, 168, 272-276.	0.8	51
339	Homozygous Protein C Deficiency: Description of a New Mutation and Successful Treatment with Low Molecular Weight Heparin. <i>Thrombosis and Haemostasis</i> , 1998, 79, 756-761.	1.8	59
340	Morphologic and Biochemical Features Affecting the Antithrombotic Properties of the Inferior Vena Cava of Rabbit Pups and Adult Rabbits. <i>Pediatric Research</i> , 1998, 43, 62-67.	1.1	20
341	Covalent Antithrombin-Heparin Complexes with High Anticoagulant Activity. <i>Journal of Biological Chemistry</i> , 1997, 272, 22111-22117.	1.6	63
342	Long-term follow up of patients with transcobalamin II deficiency.. <i>Archives of Disease in Childhood</i> , 1995, 72, 237-238.	1.0	30

#	ARTICLE	IF	CITATIONS
343	Bleeding disorders. , 0, , 286-302.		1
344	Developmental hemostasis I. , 0, , 107-118.		0
345	Pediatric Thrombosis. , 0, , 120-123.		0
346	Haematologic Conditions and Oncology. , 0, , 360-379.		0